The success of checkpoint blockade therapy revolutionized cancer treatment. However, we
need to increase the fraction of responding patients and overcome acquired resistance to …

The initial development of cytomegalovirus (CMV) as a vaccine vector for HIV/simian
immunodeficiency virus (SIV) was predicated on its potential to pre-position high-frequency …

Pathogen-specific CD8+ T cell responses restricted by the nonpolymorphic nonclassical
class Ib molecule human leukocyte antigen E (HLA-E) are rarely reported in viral infections …

Interest in MHC-E–restricted CD8+ T cell responses has been aroused by the discovery of
their efficacy in controlling simian immunodeficiency virus (SIV) infection in a vaccine model …

Human leukocyte antigen (HLA)-E binds epitopes derived from HLA-A, HLA-B, HLA-C and
HLA-G signal peptides (SPs) and serves as a ligand for CD94/NKG2A and CD94/NKG2C …

HLA-E is a non-classical class I MHC protein involved in innate and adaptive immune
recognition. While recent studies have shown HLA-E can present diverse peptides to NK …

The human body frequently encounters harmful bacterial pathogens and employs immune
defense mechanisms designed to counteract such pathogenic assault. In the adaptive …

The strain 68-1 rhesus cytomegalovirus (RhCMV)–based vaccine for simian
immunodeficiency virus (SIV) can stringently protect rhesus macaques (RMs) from SIV …

Human leukocyte antigen-E (HLA-E) normally presents an HLA class Ia signal peptide to the
NKG2A/C-CD94 regulatory receptors on natural killer (NK) cells and T cell subsets. Rhesus …

Peptides presented by HLA-E, a molecule with very limited polymorphism, represent
attractive targets for T cell receptor (TCR)-based immunotherapies to circumvent the …